Differences

This shows you the differences between two versions of the page.

--- endocrine:glp1:start [2026/02/13 00:13] – andrew2393cns
+++ endocrine:glp1:start [2026/02/13 00:14] (current) – [Clinical Pearls] andrew2393cns
@@ Line 31: / Line 31: @@
 ===== FDA-Approved GLP-1 Receptor Agonists (Chronologic Order) =====
-• [[endocrine:glp1:exenatide|Exenatide]] (2005)
+  * • [[endocrine:glp1:exenatide|Exenatide]] (2005)
-• [[endocrine:glp1:liraglutide|Liraglutide]] (2010)
+  * • [[endocrine:glp1:liraglutide|Liraglutide]] (2010)
-• [[endocrine:glp1:dulaglutide|Dulaglutide]] (2014)
+  * • [[endocrine:glp1:dulaglutide|Dulaglutide]] (2014)
-• [[endocrine:glp1:semaglutide|Semaglutide]] (2017 injectable; 2019 oral)
+  * • [[endocrine:glp1:semaglutide|Semaglutide]] (2017 injectable; 2019 oral)
 Each agent differs in half-life, dosing frequency, and cardiovascular outcome data.
@@ Line 44: / Line 44: @@
 GLP-1 receptor agonists reduce:
-• Myocardial infarction
+  * • Myocardial infarction
-• Stroke
+  * • Stroke
-• Cardiovascular death
+  * • Cardiovascular death
 Strongest ASCVD data:
-• [[endocrine:glp1:liraglutide|Liraglutide]]
+  * • [[endocrine:glp1:liraglutide|Liraglutide]]
-• [[endocrine:glp1:semaglutide|Semaglutide]]
+  * • [[endocrine:glp1:semaglutide|Semaglutide]]
-• [[endocrine:glp1:dulaglutide|Dulaglutide]]
+  * • [[endocrine:glp1:dulaglutide|Dulaglutide]]
 They are particularly beneficial in patients with established ASCVD.
@@ Line 75: / Line 75: @@
 Common:
-• Nausea
+  * • Nausea
-• Vomiting
+  * • Vomiting
-• Diarrhea
+  * • Diarrhea
-• Early satiety
+  * • Early satiety
 Serious (rare):
-• Pancreatitis
+  * • Pancreatitis
-• Gallbladder disease
+  * • Gallbladder disease
-• Medullary thyroid carcinoma risk (avoid in MEN2)
+  * • Medullary thyroid carcinoma risk (avoid in MEN2)
 --------------------------------------------------------------------
@@ Line 100: / Line 100: @@
 GLP-1 receptor agonists:
-• Strong weight loss
+  * • Strong weight loss
-• Strong ASCVD reduction
+  * • Strong ASCVD reduction
-• Minimal HF benefit
+  * • Minimal HF benefit
 [[endocrine:sglt2:start|SGLT2 Inhibitors]]:
-• Strong HF benefit
+  * • Strong HF benefit
-• Strong CKD protection
+  * • Strong CKD protection
-• Mild weight loss
+  * • Mild weight loss
 These classes are often complementary in cardiometabolic disease.
@@ Line 116: / Line 116: @@
 ===== Clinical Pearls =====
-✔ Glucose-dependent insulin release
+  * ✔ Glucose-dependent insulin release
-✔ Promote weight loss
+  * ✔ Promote weight loss
-✔ Reduce ASCVD events
+  * ✔ Reduce ASCVD events
-✔ Low hypoglycemia risk
+  * ✔ Low hypoglycemia risk
-✔ Not primary HF therapy
+  * ✔ Not primary HF therapy
-✔ Complementary to SGLT2 inhibitors
+  * ✔ Complementary to SGLT2 inhibitors
 --------------------------------------------------------------------